| Not Yet Recruiting | A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteer Healthy Volunteers | Phase 1 | 2026-04-20 |
| Recruiting | IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | 2026-04-01 |
| Not Yet Recruiting | Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity Overweight, Obesity, Hypertensive | Phase 3 | 2026-04-01 |
| Not Yet Recruiting | IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advan CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2026-03-30 |
| Not Yet Recruiting | IBI343 in Combination Therapy for Advanced Malignant Solid Tumors CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 2 | 2026-03-25 |
| Not Yet Recruiting | A Mutiple-dose Study of IBI3033 in Healthy Participants Healthy Participants | Phase 1 | 2026-03-24 |
| Recruiting | A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis Atopic Dermatitis | Phase 2 | 2026-02-06 |
| Not Yet Recruiting | A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients Hypertension | Phase 2 | 2026-02-06 |
| Not Yet Recruiting | IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer Resectable Stage II-III Non-small Cell Lung Cancer | Phase 2 | 2026-02-04 |
| Recruiting | A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis Atopic Dermatitis | Phase 2 | 2025-12-31 |
| Not Yet Recruiting | A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease Thyroid Eye Disease | Phase 4 | 2025-12-30 |
| Recruiting | A Study of IBI362 in Chinese Adolescents With Obesity or Overweight Adolescents With Obesity or Overweight With Weight-Related Comorbidities | Phase 3 | 2025-12-29 |
| Not Yet Recruiting | A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants Healthy Participants | Phase 1 | 2025-12-23 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011 Acute Gout Flare | Phase 1 | 2025-12-08 |
| Not Yet Recruiting | Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression Non-small Lung Cancer | — | 2025-10-01 |
| Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease Thyroid Eye Disease | Phase 3 | 2025-09-10 |
| Not Yet Recruiting | A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer | Phase 2 | 2025-08-31 |
| Recruiting | IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resect Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | 2025-08-26 |
| Recruiting | A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 1 Pancreatic Cancer | Phase 3 | 2025-08-04 |
| Recruiting | A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | 2025-07-01 |
| Active Not Recruiting | Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity Obesity | Phase 1 / Phase 2 | 2025-06-17 |
| Recruiting | A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 Sleep Apnea, Obstructive, Obesity | Phase 3 | 2025-06-12 |
| Recruiting | Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases Non-Small Cell Lung Cancer | — | 2025-06-04 |
| Recruiting | A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participa Asthma | Phase 1 | 2025-05-14 |
| Recruiting | A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-assoc Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Phase 3 | 2025-05-09 |
| Recruiting | IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors Unresectable Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | 2025-04-18 |
| Recruiting | A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction | Phase 2 | 2025-04-01 |
| Recruiting | Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Prim Ovarian, Primary Peritoneal, Fallopian Tube Cancer | Phase 3 | 2025-03-17 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With U Melanoma | Phase 2 | 2025-02-24 |
| Recruiting | IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors Locally Advanced Solid Tumor | Phase 1 | 2025-01-10 |
| Recruiting | Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors Unresectable, Locally Advanced or Metastatic Solid Tumors | Phase 1 | 2025-01-08 |
| Recruiting | Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer Small Cell Lung Cancer | Phase 1 | 2024-12-30 |
| Completed | A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease Thyroid Eye Disease | Phase 2 | 2024-09-04 |
| Completed | This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity Adolescents With Obesity | Phase 1 | 2024-08-30 |
| Terminated | A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors Solid Tumor | Phase 1 / Phase 2 | 2024-08-19 |
| Recruiting | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma Multiple Myeloma | Phase 1 / Phase 2 | 2024-07-29 |
| Completed | Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome Primary Sjögren's Syndrome | Phase 1 | 2024-07-14 |
| Completed | A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects Gout, Hyperuricemia | Phase 2 | 2024-07-10 |
| Recruiting | A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | 2024-06-30 |
| Recruiting | A Study of IBI363 in Subjects With Advanced Malignancies Advanced Malignancies | Phase 1 | 2024-06-15 |
| Completed | Safety and Tolerability of IBI355 in Healthy Volunteers Healthy | Phase 1 | 2024-05-20 |
| Recruiting | A Study of IBI363 in Subjects with Advanced Solid Malignancies Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer | Phase 2 | 2024-04-08 |
| Active Not Recruiting | Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer Non-Small Cell Lung Cancer | Phase 3 | 2024-03-15 |
| Completed | A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors Solid Tumor | Phase 1 / Phase 2 | 2024-03-12 |
| Completed | A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase In Gout Arthritis | Phase 1 | 2024-03-05 |
| Active Not Recruiting | A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity Type 2 Diabetes, Obesity | Phase 3 | 2024-02-29 |
| Completed | A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmati Healthy Participants, Asthma | Phase 1 | 2024-02-26 |
| Completed | A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours Locally Advanced Unresectable or Metastatic Solid Tumors | Phase 1 / Phase 2 | 2024-01-16 |
| Completed | A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients Healthy Participants, Atopic Dermatitis Patients | Phase 1 | 2024-01-05 |
| Active Not Recruiting | A Study of IBI362 9 mg in Chinese Adults With Obesity Obesity | Phase 3 | 2023-12-27 |
| Recruiting | A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors Solid Tumor | Phase 1 / Phase 2 | 2023-11-14 |
| Completed | Safety and Tolerance Study of IBI355 in Health Volunteers Healthy Subjects | Phase 1 | 2023-10-30 |
| Active Not Recruiting | A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroi Thyroid Eye Disease, TED | Phase 3 | 2023-10-20 |
| Recruiting | A Study of IBI363 in Subjects With Advanced Melanoma Melanoma | Phase 2 | 2023-10-19 |
| Completed | IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment Psoriasis | Phase 3 | 2023-10-10 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD Neovascular Age-related Macular Degeneration | Phase 3 | 2023-09-21 |
| Completed | A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics Psoriasis | Phase 2 | 2023-08-28 |
| Completed | The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximu Advanced Solid Tumors | Phase 1 / Phase 2 | 2023-08-09 |
| Terminated | The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Comb Non-squamous Non-small-cell Lung Cancer | Phase 2 | 2023-07-31 |
| Withdrawn | Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma Follicular Lymphoma | Phase 1 | 2023-07-28 |
| Recruiting | A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant MSI-H | Phase 3 | 2023-05-25 |
| Completed | Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment Renal Impairment | Phase 1 | 2023-05-05 |
| Completed | A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxi Overweight Subjects, Obese Subjects | Phase 1 | 2023-04-06 |
| Recruiting | A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors Locally Advanced Unresectable or Metastatic Solid Tumors | Phase 1 / Phase 2 | 2023-04-04 |
| Unknown | IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer Advanced Biliary Tract Cancer | Phase 1 / Phase 2 | 2023-03-10 |
| Completed | A Study of IBI351 in Healthy Subjects Healthy Subjects | Phase 1 | 2023-03-10 |
| Completed | Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers Healthy Male Subjects | Phase 1 | 2023-03-06 |
| Completed | A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration Neovascular Age-related Macular Degeneration | Phase 1 | 2023-02-27 |
| Completed | A Study of [14C]IBI351 in Healthy Subjects Healthy Subjects | Phase 1 | 2023-02-18 |
| Completed | A Study of IBI351 in Healthy Subjects Healthy Subjects | Phase 1 | 2023-02-16 |
| Completed | A Study of IBI311 in Subjects With Active Thyroid Eye Disease Thyroid Eye Disease | Phase 2 / Phase 3 | 2023-02-14 |
| Completed | A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis Psoriasis | Phase 3 | 2023-02-10 |
| Completed | A Study of IBI362 in Participants With Type 2 Diabetes Type 2 Diabetes | Phase 3 | 2023-01-06 |
| Completed | A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise Type 2 Diabetes | Phase 3 | 2023-01-06 |
| Completed | A Study of IBI353 (Orismilast) in Chinese Healthy Adults Healthy Subjects | Phase 1 | 2022-11-30 |
| Completed | A Study of IBI362 in Participants With Obesity or Overweight Obesity Or Overweight | Phase 3 | 2022-11-14 |
| Withdrawn | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metas Unresectable Cutaneous Melanoma, Metastatic Cutaneous Melanoma | Phase 1 / Phase 2 | 2022-11-01 |
| Recruiting | A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors Locally Advanced Unresectable or Metastatic Solid Tumors | Phase 1 | 2022-10-26 |
| Recruiting | Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Ca Advanced Non-Small Cell Lung Cancer | Phase 1 | 2022-09-20 |
| Unknown | Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma Solid Tumors or Lymphoma | Phase 1 | 2022-08-31 |
| Active Not Recruiting | A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Solid Malignancies or Lymphomas | Phase 1 | 2022-08-22 |
| Unknown | A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cance Colorectal Cancer | Phase 1 | 2022-08-18 |
| Completed | A Study of IBI311 in Healthy Volunteers Healthy | Phase 1 | 2022-08-10 |
| Completed | A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema Diabetic Macular Edema | Phase 1 | 2022-08-01 |
| Completed | A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis Ulcerative Colitis (UC) | Phase 2 | 2022-07-01 |
| Completed | A Study of Longer Interval of IVT IBI302 in Subjects With nAMD Neovascular Age-related Macular Degeneration | Phase 2 | 2022-06-29 |
| Withdrawn | IBI397 or Combination Therapies in Patients With Advanced Malignancies Advanced Malignancies | Phase 1 | 2022-04-14 |
| Completed | Phase I Study of Sintilimab in Healthy Chinese Male Subjects Healthy Male Subjects | Phase 1 | 2022-04-13 |
| Not Yet Recruiting | First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP Diffuse Large B-Cell Lymphoma | Phase 2 | 2022-03-25 |
| Unknown | Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Mali Advanced Solid Tumors | Phase 1 | 2022-03-22 |
| Unknown | A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors | Phase 1 | 2022-03-01 |
| Completed | A Phase I Study of IBI325 in Patients With Advanced Solid Tumor Solid Tumor | Phase 1 | 2022-02-08 |
| Terminated | A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19 COVID-19 | Phase 1 / Phase 2 | 2022-01-06 |
| Terminated | A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19 COVID-19 | Phase 1 / Phase 2 | 2021-12-31 |
| Terminated | A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor Myeloid Tumor | Phase 1 | 2021-12-28 |
| Completed | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345 CLDN18.2 Positive Solid Tumors | Phase 1 | 2021-12-13 |
| Terminated | Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuva Non-small Cell Lung Cancer (NSCLC) | Phase 1 | 2021-12-02 |
| Suspended | Evaluation of IBI302 Injection in nAMD or DME Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | Phase 1 / Phase 2 | 2021-11-18 |
| Completed | IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC) NSCLC (Non-small-cell Lung Cancer) | Phase 1 | 2021-11-12 |
| Completed | A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced Solid Tumor | Phase 1 | 2021-10-27 |
| Unknown | Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Ref DLBCL | Phase 1 | 2021-09-27 |
| Completed | A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Psoriasis | Phase 2 | 2021-09-23 |
| Completed | A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations KRAS G12C | Phase 1 / Phase 2 | 2021-09-13 |
| Completed | A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage S SCLC | Phase 1 | 2021-09-07 |
| Completed | A Study of IBI362 in Chinese Patients With Type 2 Diabetes Type 2 Diabetes | Phase 2 | 2021-09-06 |
| Completed | Study of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects Healthy Male Subjects | Phase 1 | 2021-07-30 |
| Completed | IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC NPC | Phase 1 | 2021-07-23 |
| Completed | IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors. Advanced Solid Tumor | Phase 1 | 2021-07-21 |
| Unknown | Study of IBI323 in Patients With Advanced Malignancies Advanced Malignancies | Phase 1 | 2021-06-29 |
| Completed | A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2021-06-24 |
| Completed | A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2021-06-21 |
| Completed | A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects Overweight/ Obesity | Phase 2 | 2021-06-08 |
| Completed | A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC Advanced Lung Cancer | Phase 1 | 2021-06-06 |
| Completed | A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Hea Healthy Subjects | Phase 1 | 2021-05-31 |
| Terminated | IBI188 Combination Therapy in Solid Tumors Solid Tumors, Lung Adenocarcinoma, Osteosarcoma | Phase 1 | 2021-05-25 |
| Completed | A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Ma Hematologic Malignancy | Phase 1 | 2021-05-07 |
| Unknown | Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors Advanced Malignant Tumors | Phase 1 | 2021-04-28 |
| Completed | A Study of IBI302 in Patients With nAMD Neovascular Age-related Macular Degeneration | Phase 2 | 2021-04-28 |
| Terminated | A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) Gastric Adenocarcinoma | Phase 3 | 2021-03-10 |
| Completed | Clinical Study of IBI362 in Healthy Chinese Male Subjects Overweight/Obesity | Phase 1 | 2021-03-03 |
| Completed | A Study of IBI306 in Participants With Hypercholesterolemia Hypercholesterolemia | Phase 3 | 2021-02-09 |
| Completed | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the Fir Hepatocellular Carcinoma | Phase 3 | 2021-02-07 |
| Completed | A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patient Advanced Lung Cancer | Phase 1 | 2021-01-25 |
| Completed | A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers Advanced Malignant Tumors Lymphomas | Phase 1 | 2021-01-14 |
| Terminated | A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative T Hepatocellular Carcinoma | Phase 1 | 2020-12-24 |
| Completed | A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Ver Small Cell Lung Carcinoma | Phase 1 | 2020-12-14 |
| Completed | A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer | Phase 2 | 2020-12-08 |
| Terminated | Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma Advanced Cutaneous Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2020-12-01 |
| Terminated | Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma Extranodal NK/T Cell Lymphoma, Nasal Type | Phase 1 / Phase 2 | 2020-11-24 |
| Suspended | Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS Myelodysplastic Syndromes | Phase 1 | 2020-09-30 |
| Suspended | Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients Wit Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2020-09-25 |
| Completed | Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM Type 2 Diabetes | Phase 1 / Phase 2 | 2020-09-12 |
| Terminated | IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Ins Colorectal Cancer | Phase 2 | 2020-08-27 |
| Completed | Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects Healthy Subjects | Phase 1 | 2020-08-27 |
| Suspended | A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS | Phase 1 | 2020-08-24 |
| Completed | Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors Advanced Malignancies | Phase 1 | 2020-07-31 |
| Terminated | A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor Advanced or Metastatic Solid Tumors | Phase 1 | 2020-06-29 |
| Terminated | A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host GVHD,Acute | Phase 1 / Phase 2 | 2020-06-18 |
| Completed | Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma | Phase 1 | 2020-06-16 |
| Completed | Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity S Overweight or Obesity | Phase 1 / Phase 2 | 2020-06-16 |
| Completed | Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Neovascular Age-related Macular Degeneration | Phase 1 | 2020-05-28 |
| Completed | A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunorecep Advanced Malignancies | Phase 1 | 2020-05-22 |
| Completed | Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia Hypercholesterolemia | Phase 3 | 2020-04-29 |
| Terminated | The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanom Acral Melanoma That Has Been Removed by Surgery | Phase 3 | 2020-04-17 |
| Completed | IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma Indolent Non-hodgkin Lymphoma | Phase 2 | 2020-04-07 |
| Unknown | Intense Monitoring Study on Tyvyt Relapsed or Refractory Classical Hodgkin's Lymphoma | — | 2020-04-02 |
| Completed | A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSC Advanced or Metastatic NSCLC | Phase 1 | 2020-04-02 |
| Completed | Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations Solid Tumor | Phase 1 | 2020-03-26 |
| Completed | Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Includ Cholangiocarcinoma | Phase 2 | 2020-03-03 |
| Completed | Safety and Efficacy of IBI306 in HeFH Patients Heterozygous Familial Hypercholesterolemia | Phase 3 | 2019-12-20 |
| Unknown | A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignan Advanced Malignancies | Phase 1 | 2019-12-04 |
| Completed | A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor Advanced Solid Tumor | Phase 1 | 2019-11-26 |
| Unknown | A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hod Classic Hodgkin's Lymphoma | Phase 3 | 2019-10-21 |
| Completed | A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozy Homozygous Familial Hypercholesterolemia | Phase 2 / Phase 3 | 2019-09-29 |
| Completed | Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non- Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | 2019-07-11 |
| Completed | Study of IBI318 in Participants With Advanced Malignancies Advanced Malignancy | Phase 1 | 2019-04-19 |
| Completed | A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration Neovascular Age-related Macular Degeneration | Phase 1 | 2019-04-15 |
| Completed | Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia Hypercholesterolemia | Phase 2 | 2019-03-07 |
| Completed | A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differenti Advanced Malignancies | Phase 1 | 2019-02-19 |
| Completed | First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2019-02-13 |
| Unknown | A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Ant Hepatocellular Carcinoma | Phase 2 / Phase 3 | 2019-02-11 |
| Completed | A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies Advanced Malignancies | Phase 1 | 2019-01-10 |
| Completed | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) Esophageal Squamous Cell Carcinoma | Phase 3 | 2018-12-24 |
| Completed | Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in P Gastric Cancer | Phase 3 | 2018-12-19 |
| Completed | Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced Squamous NSCLC | Phase 3 | 2018-09-28 |
| Completed | A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. Advanced Solid Tumors | Phase 1 | 2018-09-25 |
| Completed | Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC Lung Neoplasms | Phase 3 | 2018-08-23 |
| Completed | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Advanced/Metastatic Solid Malignancies | Phase 1 | 2018-06-27 |
| Completed | Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects. Hypercholesterolemia | Phase 1 | 2017-11-27 |
| Completed | A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic Non-small Cell Lung Cancer | Phase 3 | 2017-09-01 |
| Completed | Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients Effect of Drugs | Phase 2 | 2017-08-23 |
| Completed | Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatm Esophageal Squamous Cell Carcinoma | Phase 2 | 2017-05-10 |
| Completed | Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Relapsed/Refractory Classical Hodgkin's Lymphoma | Phase 2 | 2017-03-30 |
| Completed | Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male Healthy | Phase 1 | 2017-03-09 |
| Completed | A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal An B-Cell Lymphoma | Phase 1 | 2016-12-13 |
| Completed | Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC NSCLC | Phase 3 | 2016-11-28 |
| Completed | Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimum Healthy | Phase 1 | 2016-10-27 |
| Completed | First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors Cancer, Solid Tumor | Phase 1 | 2016-10-19 |
| Completed | Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis AS | Phase 3 | 2016-09-22 |
| Completed | A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B Diffuse, Large B-Cell, Lymphoma | Phase 3 | 2016-08-22 |